Icon
+91 94997 68112
Login Register

XALKORI - (200MG, 250MG ; Capsule)

CRIZOTINIB PF PRISM CV
200MG, 250MG ; Capsule
Less Than $1000 mn
None None
Less Than 5
 None
None None
XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. • adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.
Yes
XALKORI Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
*** *********
**************** **** *************** ********* ** ******* ****** ********** *************** ********* ** ******* ****** ********** ****** ** ******** ******** **** ****** **************** **** *************** ********* ** ******* ****** ********** ********** ** * *-***/**** *********

XALKORI - (20MG, 50MG, 150MG ; CAPSULE,PELLETS)

CRIZOTINIB PF PRISM CV
20MG, 50MG, 150MG ; CAPSULE,PELLETS
Less Than $1000 mn
None None
None None
None None
XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. • adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.
Yes
XALKORI Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
*** *********
**************** **** *************** ********* ** ******* ****** ********** *************** ********* ** ******* ****** ********** ****** ** ******** ******** **** ****** **************** **** *************** ********* ** ******* ****** ********** ********** ** * *-***/**** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.